What to Expect Next in Health Care Policy
This memorandum titled What to Expect Next in Health Care Policy provides insight on what to expect next in health care policy following last week’s withdrawal of the American Health…
Fighting to Preserve the Benefits of the 340B Program
This memorandum titled What to Expect Next in Health Care Policy provides insight on what to expect next in health care policy following last week’s withdrawal of the American Health…
Here is a memo summarizing the Trump administration’s proposed budget for FY 2018. Notably, the budget lists funding for Ryan White providers as one of HHS’ “highest priorities.” The memo…
The Health Resources and Services Administration (HRSA) has delayed until May 22, 2017 the effective date of the 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation,…
The Alliance for Integrity and Reform of 340B (AIR-340B), an advocacy group funded by the pharmaceutical industry and oncologists, has told Congress how to scale back the 340B Program. The…
House Republicans released last night a draft plan for repeal and replace of the Affordable Care Act (ACA). The House Energy and Commerce Committee and Ways and Means Committee each…
The U.S. Government and Accountability Office (GAO) is examining 340B contract pharmacy arrangements, although we do not yet know the purpose of the GAO’s review. The GAO is the investigative…
Several manufacturers of leading antiretroviral drugs increased wholesale acquisition cost (WAC) prices at the beginning of this year, despite an open letter submitted by the Fair Pricing Coalition and more…